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Abstract
Rationale: The reduction in upper airway muscle activity from
wakefulness to sleep plays a key role in the development of obstructive
sleep apnea. Potassium (K1) channels have been recently identified as
the downstream mechanisms through which hypoglossal motoneuron
membrane excitability is reduced both in non-rapid eye movement
(NREM) sleep and REM sleep. In animal models, the administration of
4-aminopyridine (4-AP), a voltage-gatedK1 channel blocker, increased
genioglossus activity during wakefulness and across all sleep stages.
Objectives:We tested the hypothesis that administration of a single
dose of 4-AP10mg extended releasewould increase genioglossus activity
(electromyography of the genioglossus muscle [EMGGG]) during
wakefulness and sleep, and thereby decrease pharyngeal collapsibility.
Methods:We performed a randomized controlled crossover proof-
of-concept trial in 10 healthy participants. Participants received
active treatment or placebo in randomized order 3 hours before
bedtime in the physiology laboratory.
Results: EMGGG during wakefulness and NREM sleep and upper
airway collapsibility measured during NREM sleep were unchanged
between placebo and 4-AP nights. Tonic but not phasic EMGGG during
REM sleep was higher on the 4-AP night whenmeasured as a percentage
of maximal voluntary activation (median [interquartile range] 0.3 [0.5]
on placebo vs. 0.8 [1.9] %max on 4 AP; P= 0.04), but not when measured
in mV or as a percentage of wakefulness value.
Conclusions:Asingle dose of 4-AP 10mg extended release showed
only a small increase in tonic EMGGG during REM sleep in this group
of healthy subjects. We speculate that a higher dose of 4-AP may
further increase EMGGG. However, given the potentially severe,
dose-related adverse effects of this drug, including seizures, the
administration of 4-AP does not appear to be an effective strategy
to increase genioglossus activity during sleep in humans.
Clinical Trial registered with clinicaltrials.gov (NCT02656160).
Keywords: obstructive sleep apnea; potassium channel blockers;
drug therapy
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Animal (1, 2) and human (3) research
suggests the withdrawal of norepinephrine,
serotonin, and other monoamines at the
hypoglossal motornucleus contribute to the
reduction of upper airway muscle activity
from wake to non-rapid eye movement
(NREM) sleep. Acetylcholine-induced
inhibition instead seems to play a primary
role in upper airway muscle atonia during
REM sleep through muscarinic M2
receptors (4).
The inhibition or activation of
potassium (K1) channels has more
recently been identified as the downstream
mechanism through which these
monoamines modify the motoneuron
membrane excitability both in NREM and
REM sleep (5). Thus, it may be an ideal
target for pharmacologic treatment of
obstructive sleep apnea. Opening of K1
channels produces a hyperpolarization of
neurons, thereby reducing cell excitability
(6). It has been shown that REM sleep-
mediated atonia of the genioglossus
muscle is largely dependent on the
activation of a muscarinic receptor
associated with a G-protein-coupled
inwardly rectifying K1 channel (4, 7).
Two-pore domain acid-sensitive K1
channels may instead play a role in
hypoglossal motoneuron excitability
during NREM sleep because they are
inhibited by G-protein-coupled receptors
of wake-promoting monoamines (6),
whose concentration in the central
nervous system is reduced from
wakefulness to NREM sleep.
To confirm this hypothesis, it has
recently been shown that in rats, injection
of 4-aminopyridine (4-AP) into the
hypoglossal motor nucleus causes an
increase in genioglossus activity across all
states (wakefulness, NREM, and REM
sleep). 4-AP is a selective blocker of fast
voltage-gated K1 channels in excitable
tissues and nonexcitable cells such as B and
T lymphocytes. The use of 4-AP in its
extended-release formulation, at the dose of
10 mg twice a day, is approved in humans
affected by multiple sclerosis to increase
walking ability (8).
In this study, we tested the hypothesis
that administration of 4-AP extended
release (Ampyra 10 mg; Acorda
Therapeutics, Ardsley, NY) before sleep in
healthy individuals would increase
genioglossus activity during wakefulness,
NREM, and REM sleep compared with
placebo. The primary outcome for this
study was electromyography of the
genioglossus muscle (EMGGG) during
wakefulness and sleep. EMGGG values
were expressed in microvolts (mV), as a
percentage of maximum activation during
wakefulness (%max), and as a percentage
of baseline quiet wakefulness (%wake).
As a secondary outcome, we also
assessed the effect of 4-AP on genioglossus
muscle responsiveness to negative
pressure and pharyngeal collapsibility
during sleep.
Methods
Participants
Healthy participants aged 21–65 years
were included in the study protocol.
Individuals were excluded if they had a
clinically diagnosed sleep disorder, were
taking medications known to influence
breathing or muscle physiology, or had
allergies to lidocaine, oxymetazoline-HCl,
or 4-AP. Participants with a history of
epilepsy or renal impairment were also
excluded, as this drug may increase the risk
for seizure. The protocol was approved
by the Partners Institutional Review Board
at Brigham and Women’s Hospital
(protocol #2014P001033). All subjects
provided written informed consent
before enrolment in the study.
Assessed for eligibility (n=13)
Randomized (n=13)
Allocated to placebo second (n=7)
 • Received allocated intervention (n=4)
 • Did not receive allocated intervention (n=3,
     did not tolerate the procedures)
Allocated to 4-AP second (n=6)
 • Received allocated intervention (n=6)
 • Did not receive allocated intervention (n=0)
Second study night
Analyzed (n=4)
 • Excluded from analysis (n=0)
Analyzed (n=6)
 • Excluded from analysis (n=0)
Analysis
Allocated to 4-AP first (n=7)
 • Received allocated intervention (n=7)
 • Did not receive allocated intervention (n=0)
Allocated to placebo first (n=6)
 • Received allocated intervention (n=6)
 • Did not receive allocated intervention (n=0)
First study night
Excluded (n=0)
Enrollment
Figure 1. Flowchart of the trial. 4-AP = 4-aminopyridine.
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Measurements and Equipment
Anthropometric data were collected on both
study nights. In addition to the standard
clinical polysomnography montage,
participants breathed through a sealed nasal
mask attached to a pneumotachometer
(Hans-Rudolph, Kansas City, MO)
connected to a pressure transducer
(Validyne, Northridge, CA). Mask pressure
was monitored with a second pressure
transducer (Validyne) referenced to
atmosphere.
Epiglottic pressure was determined
with a small, flexible, pressure-tipped
catheter (Millar Instruments, Houston, TX)
that was inserted through a decongested
(oxymetazoline-HCL) and anesthetized
(4% lidocaine) nostril until the tip of the
catheter was located 1–2 cm caudal to the
base of the tongue.
EMG activity from the genioglossus
(EMGGG) muscle was recorded and
quantified as described in our previous
studies (3, 9–11).
Protocol
Two overnight sleep studies were
performed 76 3 days apart: a placebo
night and a 4-AP night, with a single-
blinded (investigators), randomized
control design (see Figure 1 for the flow
chart). Randomization was performed by
the investigational pharmacy; all data
analysis and subject exclusions were
performed before unblinding of the
intervention allocation. For each night,
the subjects arrived at the sleep
laboratory at approximately 6:30 P.M.
After the measurement of baseline EMGGG
activity during wakefulness for 10 minutes,
the placebo or 4-AP was administered
approximately 3 hours before lights out.
Once the patient had been set up for
overnight monitoring, the measurements
outlined here were performed.
Wake-vs.-Sleep EMGGG at
Atmospheric Pressure
At least 10 minutes of quiet wakefulness was
recorded to quantify each subject’s awake
EMGGG activity in the lateral position. We
chose the lateral position to minimize
airway narrowing and pharyngeal pressure
swings that reflexively alter genioglossus
activity (3, 12). At least 1 hour of sleep data
were then collected during NREM and
REM sleep in the lateral position before
upper airway physiology was assessed.
Upper Airway Physiology Using
Continuous Positive Airway
Pressure Manipulation
Participants were placed supine and
connected to a positive/negative pressure
source (Philips-Respironics, Murrysville,
PA) to enable rapid switching between
pressure levels. When stable sleep was
reached, the pressure in the mask was
increased to the required level to abolish
flow limitation, as determined by the airflow
waveform and epiglottic pressure signals.
After a baseline recording period of 5
minutes, the continuous positive airway
pressure (CPAP) level was reduced to
varying suboptimal pressures using two
approaches. In the first approach, CPAP was
lowered gradually (,1 cm H2O/min) to
slowly reduce ventilation and thereby
increase epiglottic pressure swings and
pharyngeal muscle activity. During this
procedure, we assessed the EMGGG
response to progressively greater negative
epiglottic pressure swings (genioglossus
muscle responsiveness). In the second,
CPAP was lowered acutely to
subtherapeutic levels to assess the upper
airway collapsibility under eupneic
(passive) conditions. See Data Analysis for
further details. After approximately 2
hours of sleep under these conditions,
CPAP was removed and participants
returned to the lateral position to collect
additional EMGGG data at atmospheric
pressure.
Data Analysis
The raw EMGGG was processed and
quantified in microvolts (mV) as a
percentage of maximal voluntary
activation (%max), as previously described
(13), and as percentage of quiet
wakefulness (%wake) for between-night
comparison of baseline sleep EMGGG
activity. The patient was asked to perform
several maneuvers to determine maximum
genioglossus activity, including swallowing
and maximally pushing the tongue against
the front upper or lower teeth.
EMGGG analysis was performed on a
breath-by-breath basis identifying a
maximum and a minimum value during
inspiration and expiration, respectively
(EMGGG peak and tonic). The difference
between peak and tonic values was used to
estimate the respiratory-related phasic
activity.
Table 1. Characteristics of the patients
analyzed (N=10)
Characteristic
Female sex, n (%) 6 (60)
Age, yr 26.0 [10]
Body mass index, kg/m2 24.5 [7.4]
Neck circumference, cm 38.0 [8.3]
Waist circumference, cm 94.5 [22.0]
Data are presented as median [interquartile
range] unless otherwise specified.
Table 2. Activity of genioglossus muscle during sleep
Placebo 4-AP P value
NREM tonic
mV 10.8 [11.0] 7.5 [18.2] 0.49
%max 0.8 [1.1] 0.7 [1] 0.38
%wake 167 [185] 136 [354] .0.5
NREM phasic
mV 9.4 [14.3] 5.4 [26.7] 0.38
%max 0.5 [1.5] 0.6 [1.5] 0.28
%wake 245 [228] 163 [500] 0.32
REM tonic
mV 3.9 [6.5] 10.6 [20.8] .0.5
%max 0.3 [0.5] 0.8 [1.9] 0.04
%wake 83 [80] 92 [212] .0.5
REM phasic
mV 5.0 [16.3] 0.8 [12.1] 0.46
%max 0.5 [0.9] 0.4 [3.6] 0.38
%wake 170 [523] 144 [387] .0.5
Definition of abbreviations: 4-AP = 4-aminopyridine; NREM= non-rapid eye movement sleep;
REM= rapid eye movement sleep.
Data are expressed as median [interquartile range]. REM values reflect both active periods
characterized by sporadic muscle twitches and passive periods characterized by muscle atonia.
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Wakefulness EMGGG values were
obtained from a minimum of 10 epochs
(30 seconds each) from the subject lying in
the lateral position at baseline and after
approximately 3 hours from drug
administration.
EMGGG values during sleep were
matched for the same epiglottic pressures
ranges between nights during NREM and
REM sleep.
Apneas and hypopneas were scored
using standard American Academy of Sleep
Medicine guidelines (14), and the arousal
and apnea–hypopnea indices reported are
the value taken while the participants slept
without CPAP.
As described in previous studies (13,
15), for each participant, we also measured
the genioglossus responsiveness to negative
pressure (slope of EMGGG) and the
passive upper airway collapsibility.
Statistical Analysis
Variables were compared using Wilcoxon
matched-pairs signed rank test, with
P, 0.05 considered statistically significant.
Data are expressed as a median
(interquartile range). Statistical analyses
were performed using Prism 6.0 (Graph
Pad Software, La Jolla, CA).
Results
Participants
A total of 13 patients were enrolled in the
study. Three patients did not tolerate the
study setup, and for this reason, they did not
come back for the second study night.
Therefore, data from 10 participants were
analyzed for upper airway physiology on
both nights. The characteristics of these
patients are described in Table 1. One
patient experienced a mild headache 2 hours
after 4-AP administration. The symptom
spontaneously disappeared 1 hour later.
Effect of 4-AP on EMGGG Activity
during Wakefulness
The number of breaths analyzed during
wakefulness before placebo/drug
administration was 1116 37 during
placebo night and 936 43 during 4-AP
night. Three hours after placebo/drug
administration, 1516 98 breaths were
analyzed on the placebo night versus 1146
90 breaths on the 4-AP night. Maximum
voluntary EMGGG was similar between
nights (701 [332] on placebo vs. 625 [414] mV
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Figure 2. Genioglossus activity and epiglottic pressure across sleep stages during placebo and
4-aminopyridine (4-AP) nights. Group data representing tonic (upper), phasic (middle) genioglossus
activity (EMGGG), and epiglottic pressure swings (lower). There was no significant difference between
placebo and 4-AP in EMGGG for any sleep stage analyzed when measured as a percentage of
wakefulness value. The EMGGG was matched for the same range of epiglottic pressure swings
(median value during placebo night 6 1 cm H2O). Dots indicate median values, and lines indicate
25th (low) and 75th (top) percentiles. Rapid eye movement (REM) passive refers to periods of relative
atonia during REM sleep, whereas REM active refers to periods characterized by prolonged muscle
twitches. NREM1, NREM2, and NREM3 = non-rapid eye movement sleep stages 1, 2, and 3.
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on 4-AP; P. 0.5) There was no difference
in awake %max EMGGG activity before and
after 4-AP administration for both tonic
(0.32 [0.89] vs. 0.73 [0.97]; P. 0.5) and
phasic activity (0.24 [0.98] vs. 0.51 [0.66];
P. 0.5). There was also no difference in
EMGGG activity, expressed as a percentage
of baseline wakefulness, between placebo
and 4-AP nights 3 hours after placebo/drug
administration (tonic: 110 [42] on placebo
vs. 97 [150] %wake on 4-AP [P. 0.5];
phasic: 114 [70] on placebo versus
103 [99] %wake on 4-AP; P. 0.5).
Effect of 4-AP on EMGGG Activity
during Sleep
The number of breaths analyzed during
NREM sleep (off CPAP) was 1,0066 449
during placebo nights and 8556 452
during 4-AP nights. REM sleep off CPAP
was present on both nights in eight of
the 10 subjects, and the number of
breaths analyzed was 3856 219 for
placebo nights and 3046 203 for 4-AP
nights.
Group data comparing EMGGG
expressed as mV, %max, and %wake during
sleep between nights are presented in
Table 2 and Figure 2, respectively. There
was no difference in tonic or phasic
EMGGG activity during NREM sleep
between placebo and 4-AP nights. Tonic
EMGGG activity was higher during REM
sleep on 4-AP compared with placebo,
but only when expressed as %max
(Figure 3). Phasic EMGGG activity
during REM was not consistently altered
by 4-AP (Table 2). EMGGG values during
REM sleep reflect both active periods
characterized by sporadic muscle twitches
and passive periods characterized by
relative atonia, as 4-AP increased EMGGG
activity in both these periods in animal
models (5).
Genioglossus Responsiveness
Genioglossus muscle responsiveness to
progressively larger epiglottic pressure
swings were unchanged between placebo
and 4-AP nights as a group. However, seven
of 10 participants had improvement in
muscle responsiveness on 4-AP compared
with placebo (Figure 4).
Effects on Upper Airway Collapsibility
Passive upper airway collapsibility was
calculated in eight of 10 participants on both
nights. One participant did not tolerate
CPAP drops, and it was not possible to
obtain flow-limited breaths during CPAP
manipulation during placebo night in
another participant. In the remaining
eight participants, there was no significant
difference in passive upper airway collapsibility
between placebo and 4-AP nights (27.6 [7.8]
on placebo vs. 24.8 [5.0] cm H2O on 4-AP;
P= 0.20).
Effects on Sleep
4-AP had no significant effect on sleep
efficiency or architecture. The arousal index
was also similar between nights (Table 3).
All subjects had an apnea–hypopnea index
lower than 1 on both nights with the
exception of subject 8, who had an apnea–
hypopnea index of 7 on placebo versus one
event/hour on 4-AP.
Discussion
The main finding of this study was that
4-AP increased EMGGG tonic activity
during REM sleep. However, the increase in
genioglossus activity was mild and reached
the statistical significance only when
measured as a percentage of maximal
voluntary activation, not when measured in
mVs or as a percentage of quiet wakefulness.
Compared with placebo, genioglossus
activity on 4-AP was unchanged during
wakefulness or NREM sleep. Genioglossus
muscle responsiveness to progressively
greater epiglottic pressure swings and upper
airway collapsibility during sleep were also
unchanged between nights.
To our knowledge, this is the first time
the effect of a K1 channel blocker on
genioglossus activity in humans has been
tested. Previous research performed in
vitro in rat respiratory muscles showed
that administration of 4-AP and
tetraethylammonium increased the twitch
force of sternohyoid and diaphragm
muscles (16). Topical administration of a
K1 channel blocker named AVE0118 in
pigs upper airways showed a significant
reduction in upper airway collapsibility
mediated by increased genioglossus muscle
activity during drug-induced sleep (17).
More recently, studies in freely behaving
rats have confirmed that blockade of
potassium channels with several agents
(barium, 4-AP, tetraethylammonium)
constitutes an efficient strategy to increase
genioglossus activity and reverse NREM
hypotonia and REM atonia during sleep
(5). Previous studies of 4-AP in humans
revealed this drug was capable of
reversing opioid-related respiratory
depression in the postoperative setting
(18, 19). Furthermore, it is currently
prescribed to improve motor functions in
people suffering from multiple sclerosis (8),
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Figure 3. Individual data showing a significant
increase of tonic genioglossus activity (EMGGG)
on 4-aminopyridine (4-AP) compared with
placebo in eight participants in whom REM
sleep was recorded on both study nights. This
finding was limited to EMGGG expressed as
percentage of maximal voluntary activity (%max,
see Table 2 and text for explanation). Horizontal
lines indicate median values.
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Figure 4. Individual data showing genioglossus
muscle responsiveness on placebo (P) and
4-aminopyridine (4-AP). Although there was no
statistically significant effect of 4-AP as a group,
seven of 10 subjects had an improvement in
genioglossus muscle responsiveness to
progressively greater epiglottic pressure swings
evaluated during slow continuous positive airway
pressure dial down. However, with the exception
of one participant, the improvement was minimal.
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an inflammatory disease of the central
nervous system characterized by axonal
demyelination. Indeed, it has been shown
that in the presence of demyelinated
neurons, blockade of K1 channels leads
to a dose-dependent increase in action
potential amplitude and duration in animal
models (20).
The most likely reason for the lack of an
important effect of 4-AP on EMGGG activity
in our study is the small dose of the drug
administered (10 mg by mouth). However,
given its narrow therapeutic window,
raising the 4-AP dose would be unsafe, as it
would increase the risk for seizures and
other severe adverse effects resulting from
the wide distribution of voltage-gated
K1 channels in the human body, as
demonstrated in clinical trials performed in
patients with multiple sclerosis (21). The
recent identification of a subfamily of
potassium channels named G-coupled
inwardly rectifying K1 channels 2.4, whose
distribution is largely limited to cranial
motoneurons, opens the possibility of a
more specific pharmacological target to be
tested in future (5).
Limitations
Our study had several limitations. First, the
study could be underpowered to establish
the inefficacy of 4-AP on genioglossus
activity, especially for the genioglossus
muscle responsiveness to progressively
greater epiglottic pressure swings, given that
seven of 10 participants had an increase in
genioglossus activity when receiving the
drug compared with placebo. However, the
mean difference was small (20.236
0.73%max/cm H2O), and to detect this
difference with statistical significance, we
would need to study 81 subjects, which is not
feasible considering the techniques used.
Second, the increase in REM EMGGG tonic
activity needs to be interpreted with caution:
the raw EMG amplitude may vary with the
electrodes and their site of insertion. For this
reason, it is a common practice to normalize
the raw data (mV) by the maximal EMGGG
activity during wakefulness or by the median
wakefulness values (3, 22) collected over
several minutes’ recordings and without
movement artifacts. Despite this, even the
normalization procedures can be problematic
as the maximum maneuvers are effort-
dependent and may vary between nights, and
wakefulness values can be affected by
behavioral components that may be different
from night to night.
Nevertheless, we found that
wakefulness values and maximal maneuvers
were very similar on and off the drug,
suggesting 4-AP has no substantial effect on
wakefulness and NREM EMGGG, but may
have some minor effect on tonic REM
activity. However, given that this finding is
limited to EMGGG when expressed as a
percentage of the maximum activation, it
needs to be confirmed with further
investigation. Third, we administered 4-AP
only for 1 night, and we cannot exclude that
a prolonged administration at the
recommended dose of 10 mg twice daily
could lead to different results, given that it
was shown that 15 days of continuous
administration of 4-AP 7.5 mg extended
release twice a day increased the plasma
concentration of 4-AP compared with the
single dose in a group of healthy volunteers
(23). As the main outcome of this study was
to determine the effect of 4-AP on
genioglossus muscle, we decided to study
healthy volunteers, as their sleep is
characterized by long periods of stable
breathing in every sleep state. These periods
allow a more reliable measurement of
EMGGG compared with the highly variable
breathing pattern of patients with obstructive
sleep apnea, in whom sleep is also frequently
fragmented by arousals. However, given the
difference in upper airway anatomy and
physiology between patients with obstructive
sleep apnea and normal patients (24), it may be
possible that a study performed in patients
with obstructive sleep apnea leads to different
conclusions
Conclusions
In this study, we assessed the effect of the
potassium channels blocker 4-AP on
genioglossus activity and showed that it may
have a small effect on tonic genioglossus
activity in REM. Despite a strong rationale,
blockade of K1 channels with 4-AP is not
likely a feasible strategy to improve upper
airway dilator muscle activity during sleep,
possibly because of the low dose of 4-AP
that can be safely administered in humans.
Future research should be oriented toward
an antagonist of a K1 channel whose
expression is limited to the hypoglossal
motor nucleus, or at least a limited number
of cell types to reduce the adverse effects
related to this pharmaceutical class. n
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